Balanced news tone
News Sentiment
FYB sentiment intelligence
Formycon AG news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-1.7% over one week, -8.5% over four weeks, trend inactive, and below fair value.
Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Jul 2026 20:38
- Source
- Market source
OneSource bags biosimilar manufacturing contract from Formycon
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Jul 2026 10:09
- Source
- ETPharma.com
OneSource Falls 3% on Formycon Manufacturing Deal
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 14 Jul 2026 09:01
- Source
- Equitypandit
OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 08:33
- Source
- The Economic Times
OneSource Specialty Pharma Partners With Germany's Formycon for Biosimilars Manufacturing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 07:27
- Source
- Trade Brains
OneSource Specialty Pharma ties up with Germany’s Formycon for Biosimilar manufacturing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 06:48
- Source
- BusinessLine
ONESOURCE Specialty Pharma Signs Strategic Manufacturing Deal With Formycon AG For 5 Global Biosimilars
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Jul 2026 06:46
- Source
- Sahi
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 Dec 2025 08:00
- Source
- PR Newswire
Zydus to enter US biosimilar market via Keytruda partnership with Germany's Formycon
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 Dec 2025 08:00
- Source
- Moneycontrol.com
Zydus and Formycon ink licensing agreement for biosimilar in US, Canada
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Dec 2025 08:00
- Source
- Business Standard
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 04 Dec 2025 08:00
- Source
- PR Newswire
Settlement ends Formycon and Johnson & Johnson FYB202 biosimilar dispute
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Apr 2024 07:00
- Source
- JUVE Patent
Formycon Ag Stock Price Forecast. Should You Buy FYB.DE?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 22 Dec 2020 15:47
- Source
- StockInvest.us
Formycon AG: Target Price Consensus and Analysts Recommendations | FYB | DE000A1EWVY8
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 19 Aug 2020 17:22
- Source
- marketscreener.com